Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0036690 (
sepsis
)
59,461
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
According to publicly available transcriptome datasets, the abundance of
Annexin A3
(
ANXA3
) is robustly increased during the course of
sepsis
; however, no studies have examined the biological significance or clinical relevance of
ANXA3
in this pathology. Here we explored this interpretation gap and identified possible directions for future research. Based on reference transcriptome datasets, we found that
ANXA3
expression is restricted to neutrophils, is upregulated in vitro after exposure to plasma obtained from septic patients, and is associated with adverse clinical outcomes. Secondly, an increase in
ANXA3
transcript abundance was also observed in vivo, in the blood of septic patients in multiple independent studies.
ANXA3
is known to mediate calcium-dependent granules-phagosome fusion in support of microbicidal activity in neutrophils. More recent work has also shown that
ANXA3
enhances proliferation and survival of tumour cells via a Caspase-3-dependent mechanism. And this same molecule is also known to play a critical role in regulation of apoptotic events in neutrophils. Thus, we posit that during
sepsis
ANXA3
might either play a beneficial role, by facilitating microbial clearance and resolution of the infection; or a detrimental role, by prolonging neutrophil survival, which is known to contribute to
sepsis
-mediated organ damage.
...
PMID:Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data. 3268 35